Watchlist

Watchlist
Alexion Pharmaceuticals, Inc. (ALXN)
Alexion Pharmaceuticals, Inc. (ALXN)
Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering
Content Analysis of coverage: REGN Stocks in the news: LLY, SNY, BLUE Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & An…
Argenx: This ASH Winner Has Further Upside Ahead
Shares of Argenx ( ARGX ) have risen by 125% since its addition to the ROTY 10 stock model account and my initial article in mid-November advising of several catalysts in the near term. ARGX data by YCharts Part of the original bullish thesis was centered on the promise of first-in-class…
Biotech Forum Daily Digest: Revisiting Neos Therapeutics
"He had just about enough intelligence to open his mouth when he wanted to eat, but certainly no more." - P.G. Wodehouse The main biotech indices rose some two percent on Friday to close the week relatively flat. Most of the early part of the week we saw weakness across the biotech sector,…
Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting
-- Data Demonstrate Rapid and Sustained Reduction of Plasma Lactate Dehydrogenase (LDH) -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today the presentation of comprehensive dose-ranging data from two Phase 1b/2 studies of ALXN1210, the Companys investigational long…
Game Plan For The Week - Cramer's Mad Money (12/8/17)
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, December 8. Friday's job report had something good for everyone. It has good manufacturing growth, businesses that wants interest rates to stay low and there's enough for the Fed to tighten interest…
Akari's Coversin successful in mid-stage PNH study
A Phase 2 clinical trial, COBALT , assessing Akari Therapeutics' (NASDAQ: AKTX ) lead candidate Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH) met the primary endpoint of a statistically significant reduction in LDH (lactate dehydrogenase) to within 1.8x the upper lim…
Premarket Gainers as of 9:05 am
STDY +35% . More news on: SteadyMed, Globus Maritime Ltd., Sigma Designs, Inc., Stocks on the move, Read more …
Alexion +2.6% on report Elliott has taken activist stake
Activist Elliott Management has turned its sights on Alexion Pharmaceuticals (NASDAQ: ALXN ), taking a stake in the biopharma and pushing for ways to lift its share price, The New York Times reports. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov…
Alexion licenses Halozyme's ENHANZE for up to four targets
Alexion Pharmaceuticals ( ALXN -1.6% ) inks a license and collaboration agreement with Halozyme Therapeutics ( HALO +1.4% ) for the rights to use the latter's ENHANZE drug-delivery technology in up to four candidates, including a next-generation subcutaneous formulation of ALXN1210 whi…
Alexion and Halozyme Enter License Agreement for ENHANZE Technology
--Halozyme to Receive $40 Million Upfront Payment, Future Milestones and Royalties-- --Provides Alexion Access to ENHANZE Technology for up to Four Targets-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced today a collaboration …
Alexion Pharmaceuticals, Inc. (ALXN)